Never fear, makers of anti-TNF giants: Those pesky biosimilars? They won’t be halting revenue growth anytime soon, Leerink Partners analysts predict. Taking into account current trends in prescription ...
Getting your Trinity Audio player ready... A federal judge has thrown out Amgen’s lawsuit against the state board empowered to set price ceilings on prescription drugs deemed unaffordable in Colorado, ...
Mylan has joined with India’s Lupin to market a biosimilar of Amgen/Pfizer’s inflammatory diseases blockbuster Enbrel (etanercept) in ex-US markets. Approved in a range of diseases including ...
THOUSAND OAKS, Calif., and RADNOR, Penn., – New data from multiple studies evaluating the use of ENBREL® (etanercept), the only fully human TNF receptor, in patients with long-standing disease, as ...
Oct. 14, 2004 — The U.S. Food and Drug Administration (FDA) has approved caspofungin acetate for the empiric treatment of presumed fungal infections in the setting of febrile neutropenia, etanercept ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback